The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives
Cancers · 27.01.2025 · 17 (3) · 428
DOI: 10.3390/cancers17030428 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.01.2025. Verfasst von Mitsunobu Takeda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Colorectal cancer (CRC) remains a leading cause of cancer mortality globally, with KRAS mutations occurring in 30–40% of cases, contributing to poor prognosis and resistance to anti-EGFR therapy. This review explores the biological significance, clinical implications, and therapeutic targeting of KRAS mutations in CRC.
Methods
A comprehensive analysis of the existing literature and clinical trials was performed, highlighting the role of KRAS mutations in CRC pathogenesis, their impact on prognosis, and recent advancements in targeted therapies. Specific attention was given to emerging therapeutic strategies and resistance mechanisms.
Results
KRAS mutations drive tumor progression through persistent activation of MAPK/ERK and PI3K/AKT signaling pathways. These mutations influence the tumor microenvironment, cancer stem cell formation, macropinocytosis, and cell competition. KRAS-mutant CRC exhibits poor responsiveness to anti-EGFR monoclonal antibodies and demonstrates primary and acquired resistance to KRAS inhibitors. Recent breakthroughs include the development of KRAS G12C inhibitors (sotorasib and adagrasib) and promising agents targeting G12D mutations. However, response rates in CRC remain suboptimal compared to other cancers, necessitating combination therapies and novel approaches, such as vaccines, nucleic acid-based therapeutics, and macropinocytosis inhibitors.
Conclusions
KRAS mutations are central to CRC pathogenesis and present a significant therapeutic challenge. Advances in KRAS-targeted therapies offer hope for improved outcomes, but resistance mechanisms and organ-specific differences limit efficacy. Continued efforts in personalized treatment strategies and translational research are critical for overcoming these challenges and improving patient survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
ORCID-Profile: Mitsunobu Takeda, Yuki Sekido, Mamoru Uemura
Zitieren
APA
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., Doki, Y., & Eguchi, H. (2025). The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. Cancers, 17(3), 428. https://doi.org/10.3390/cancers17030428
Vancouver
Takeda M, Yoshida S, Inoue T, Sekido Y, Hata T, Hamabe A, et al. The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. Cancers. 2025;17(3):428. doi:10.3390/cancers17030428
BibTeX
@article{Takeda2025,
author = {Takeda, Mitsunobu and Yoshida, Shoma and Inoue, Takuya and Sekido, Yuki and Hata, Tsuyoshi and Hamabe, Atsushi and Ogino, Takayuki and Miyoshi, Norikatsu and Uemura, Mamoru and Yamamoto, Hirofumi and Doki, Yuichiro and Eguchi, Hidetoshi},
title = {The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives},
journal = {Cancers},
year = {2025},
volume = {17},
number = {3},
pages = {428},
doi = {10.3390/cancers17030428}
}
EUVIMED